Skip to Main Content

A Phase II Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Conditions

Breast - Female | Breast - Male | Lung | Pancreas | Phase I

Phase II

What is the purpose of this trial?

This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body or cannot be removed by surgery, including breast cancer, non-small cell lung cancer, small cell lung cancer, and pancreatic cancer. Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also block the flow of oxygen to the tumor, and may help make the tumor more sensitive to olaparib.

  • Trial with
    National Cancer Institute
  • Start Date
    08/11/2016
  • End Date
    06/29/2019
Trial Image

For more information about this study, contact:

Nicole Sinclair

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/09/2018
  • Study HIC
    #1604017576